Írland - enska - HPRA (Health Products Regulatory Authority)

pharma nord aps - melatonin - film-coated tablet - 3 milligram(s) - melatonin

Armenía - enska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

advance pharma gmbh - pantoprazole (pantoprazole sodium sesquihydrate) - tablets gastro-resistant - 40mg

Armenía - enska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

advance pharma gmbh - pantoprazole (pantoprazole sodium sesquihydrate) - tablets gastro-resistant - 20mg

Bandaríkin - enska - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam is indicated for relief of the signs and symptoms of osteoarthritis [ see clinical studies (14.1)]. meloxicam is indicated for relief of the signs and symptoms of rheumatoid arthritis [ see clinical studies (14.1) ]. meloxicam is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients who weighs ≥ 60 kg [ see dosage and administration ( 2.4) and clinical studies (14.2)]. meloxicam is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [ see warnings and precautions ( 5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometime

Írland - enska - HPRA (Health Products Regulatory Authority)

silver pharma s.l. - mercaptopurine - tablet - 50 milligram(s) - mercaptopurine

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fulvestrant 50 mg/ml;  ;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml     excipient: benzyl alcohol benzyl benzoate castor oil ethanol - fulvestrant ever pharma is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: · previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Bandaríkin - enska - NLM (National Library of Medicine)

advanced pharmaceutical technology, inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate injection, usp is indicated for replacement therapy in tho male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectorny. 2. hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. 1. known hypersensitivity to lhe drug 2. males with carcinoma of the breast 3. males with known or suspected carcinoma of the prostate gland 4. women who are pregnant (see precutions, pregnancy) 5. palients with serious cardiac, hepatic or renal disease (see warnings) testosterone cypionate injection contains testosterone, a schedule ill controlled substance in the controlled substances act. drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. abuse and misuse of testosterone are seen in male and female adults and adolescents. testosterone, often in combination with other anabolic androgenic steroids (aas), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. there have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest. myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression. the following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. the following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. the following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. behaviors associated with addiction continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors: - taking greater dosages than prescribed - continued drug use despite medical and social problems due to drug use - spending significant time to obtain the drug when supplies of the drug are interrupted - giving a higher priority to drug use than other obligations - having difficulty in discontinuing the drug despite desires and attempts to do so - experiencing withdrawal symptoms upon abrupt discontinuation of use physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism. drug dependence in individuals using approved doses of testosterone for approved indications has not been documented.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

advance health products pty ltd - magnesium phosphate,ubidecarenone -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

advance health products pty ltd - magnesium phosphate,ubidecarenone -

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

advanced nutrients pty ltd - alcohol ethoxylate | phosphate esters of alcohol ethoxylate - adjuvant - agricultural chemical additive | herbicide additive | activator | penetrant | post emergent herbicide | spray activator | spread - acidifier | spreading agent | to lower ph